Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15147492 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ALOX12RAB9ASMN1; SMN2HPGD | |
| SCHEMBL16884595 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ALOX12RAB9ASMN1; SMN2HPGD | |
| SCHEMBL23915498 | 0.98 | SMN1; SMN2 (0.31) | ALDH1A1ALOX12RAB9ASMN1; SMN2HPGD | |
| SCHEMBL422072 | 0.89 | — | — | |
| SCHEMBL15147540 | 0.89 | ALDH1A1 (0.31) | ALDH1A1ALOX12SMN1; SMN2HPGD | |
| SCHEMBL19658247 | 0.87 | PSMB8 (0.32) | ALOX12 | |
| SCHEMBL17776322 | 0.87 | PSMB8 (0.32) | ALOX12 | |
| SCHEMBL410465 | 0.87 | PSMB8 (0.32) | ALOX12 | |
| SCHEMBL19658254 | 0.87 | PSMB8 (0.32) | ALOX12 | |
| SCHEMBL17776321 | 0.87 | PSMB8 (0.32) | ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI INC. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193478-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | ALDH1A1 2699/4885ALOX12 4373/4885RAB9A 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.